Advanced glycation end products (AGEs), formed through the nonenzymatic reaction of
reducing sugars with the side-chain amino groups of lysine or arginine of proteins, followed …

Significance: Atherosclerotic cardiovascular diseases (ACVDs) continue to be a primary
cause of mortality worldwide in adults aged 35–70 years, occurring more often in countries …

Glucose and fructose metabolism originates the highly reactive byproduct methylglyoxal
(MG), which is a strong precursor of advanced glycation end products (AGE). The MG has …

Advanced glycation end products (AGEs) are a family of compounds of diverse chemical
nature that are the products of nonenzymatic reactions between reducing sugars and …

Diabetes and its vascular complications affect an increasing number of people. This disease
of epidemic proportion nowadays involves abnormalities of large and small blood vessels …

Methylglyoxal was shown to impair adipose tissue capillarization and insulin sensitivity in
obese models. We hypothesized that glyoxalase-1 (GLO-1) activity could be diminished in …

In this study we investigate pyridoxamine (PM) and/or sulforaphane (SFN) as therapeutic
interventions to determine whether activators of NFE2-related factor 2 (Nrf2) can be used in …

Recent research shows that energy metabolism can strongly influence proteostasis and
thereby affect onset of aging and related disease such as Parkinson's disease (PD) …

Doxorubicin (DOX) is commonly used in cancer treatment but associated with cardiotoxicity.
Pyridoxamine (PM), a vitamin B6 derivative, could be a cardioprotectant. This study …

Advanced glycation end products (AGEs) play a key role in the progression of heart failure.
Whether treatments limiting AGEs formation would prevent adverse left ventricular …